These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 24118079

  • 1. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
    Peura DA, Pilmer B, Hunt B, Mody R, Perez MC.
    Aliment Pharmacol Ther; 2013 Nov; 38(10):1303-11. PubMed ID: 24118079
    [Abstract] [Full Text] [Related]

  • 2. The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
    Peura DA, Pilmer B, Hunt B, Mody R, Perez MC.
    Aliment Pharmacol Ther; 2013 Apr; 37(8):810-8. PubMed ID: 23451835
    [Abstract] [Full Text] [Related]

  • 3. Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease.
    Gold BD, Pilmer B, Kierkuś J, Hunt B, Perez MC, Gremse D.
    Dig Dis Sci; 2017 Nov; 62(11):3059-3068. PubMed ID: 28916953
    [Abstract] [Full Text] [Related]

  • 4. Obesity does not affect treatment outcomes with proton pump inhibitors.
    Sharma P, Vakil N, Monyak JT, Silberg DG.
    J Clin Gastroenterol; 2013 Sep; 47(8):672-7. PubMed ID: 23442835
    [Abstract] [Full Text] [Related]

  • 5. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.
    Fass R, Chey WD, Zakko SF, Andhivarothai N, Palmer RN, Perez MC, Atkinson SN.
    Aliment Pharmacol Ther; 2009 Jun 15; 29(12):1261-72. PubMed ID: 19392864
    [Abstract] [Full Text] [Related]

  • 6. Dual Delayed-Release Dexlansoprazole for Healing and Maintenance of Healed Erosive Esophagitis: A Safety Study in Adolescents.
    Gremse D, Gold BD, Pilmer B, Hunt B, Korczowski B, Perez MC.
    Dig Dis Sci; 2019 Feb 15; 64(2):493-502. PubMed ID: 30390234
    [Abstract] [Full Text] [Related]

  • 7. Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease.
    Wu MS, Tan SC, Xiong T.
    Aliment Pharmacol Ther; 2013 Jul 15; 38(2):190-201. PubMed ID: 23718547
    [Abstract] [Full Text] [Related]

  • 8. Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease.
    Croxtall JD, Scott LJ.
    Drugs; 2010 Aug 20; 70(12):1593-601. PubMed ID: 20687622
    [Abstract] [Full Text] [Related]

  • 9. Dexlansoprazole for the treatment of esophagitis and GERD.
    Davies SL.
    Drugs Today (Barc); 2010 Feb 20; 46(2):75-80. PubMed ID: 20393635
    [Abstract] [Full Text] [Related]

  • 10. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
    Fass R, Inadomi J, Han C, Mody R, O'Neil J, Perez MC.
    Clin Gastroenterol Hepatol; 2012 Mar 20; 10(3):247-53. PubMed ID: 22155561
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study.
    Lin XH, Luo JC, Ting PH, Chang TE, Huang YH, Hou MC, Lee FY.
    J Gastroenterol Hepatol; 2020 Dec 20; 35(12):2096-2102. PubMed ID: 32401385
    [Abstract] [Full Text] [Related]

  • 12. Impact of regurgitation on health-related quality of life in gastro-oesophageal reflux disease before and after short-term potent acid suppression therapy.
    Kahrilas PJ, Jonsson A, Denison H, Wernersson B, Hughes N, Howden CW.
    Gut; 2014 May 20; 63(5):720-6. PubMed ID: 23831734
    [Abstract] [Full Text] [Related]

  • 13. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.
    Abel C, Desilets AR, Willett K.
    Ann Pharmacother; 2010 May 20; 44(5):871-7. PubMed ID: 20371754
    [Abstract] [Full Text] [Related]

  • 14. Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
    Emerson CR, Marzella N.
    Clin Ther; 2010 Aug 20; 32(9):1578-96. PubMed ID: 20974316
    [Abstract] [Full Text] [Related]

  • 15. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.
    Metz DC, Howden CW, Perez MC, Larsen L, O'Neil J, Atkinson SN.
    Aliment Pharmacol Ther; 2009 Apr 01; 29(7):742-54. PubMed ID: 19210298
    [Abstract] [Full Text] [Related]

  • 16. Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data.
    Metz DC, Pilmer BL, Han C, Perez MC.
    Am J Gastroenterol; 2011 Nov 01; 106(11):1953-60. PubMed ID: 21844923
    [Abstract] [Full Text] [Related]

  • 17. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
    Bytzer P, van Zanten SV, Mattsson H, Wernersson B.
    Aliment Pharmacol Ther; 2012 Oct 01; 36(7):635-43. PubMed ID: 22860764
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of Amla (Phyllanthus emblica L.) in non-erosive reflux disease: a double-blind, randomized, placebo-controlled clinical trial.
    Karkon Varnosfaderani S, Hashem-Dabaghian F, Amin G, Bozorgi M, Heydarirad G, Nazem E, Nasiri Toosi M, Mosavat SH.
    J Integr Med; 2018 Mar 01; 16(2):126-131. PubMed ID: 29526236
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.